Oventus grows DTC sales channel
By HME News Staff
Updated 10:54 AM CDT, Thu October 28, 2021
BRISBANE, Australia – Oventus had revenue of $221,000 for its fiscal first quarter 2022, in line with the previous quarter. Its direct-to-consumer sales channel grew, with visits more than doubling, from 118,000 to 247,000, over the prior quarter. “While the COVID pandemic continues to hamper patient volumes for some of our clinical partners in the U.S., Australia and Canada, it is very pleasing to see our DTC marketing program achieving positive results,” said Dr. Chris Hart, managing director. “With limited options available to seek in-person consultations, patients with sleep apnea are actively searching for alternate treatment solutions, which is a reflection of our strong lead generation during the quarter.” Although most of the company’s focus is now on the DTC sales channel, Oventus observed a gradual reopening of Virtual Lab-in-Lab sites in Canada and unit sales growth in Australia during the quarter. Within the U.S., the company has entered into in-network insurance contracts that also delivered a strong increase in conversion rates from people showing interest in becoming a patient/customer.
Comments